Doxofylline

CAT: 0804-HY-B0004-01Size: 100 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0004-01Size:100 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation) . Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm[1][2][3].
CAS Number
[69975-86-6]
UNSPSC
12352005
Hazard Statement
H302
Target
Adenosine Receptor; Phosphodiesterase (PDE) ; Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Doxofylline.html
Purity
99.97
Solubility
DMSO : 50 mg/mL (ultrasonic) |H2O : 25 mg/mL (ultrasonic)
Smiles
O=C(N1C)N(C)C2=C(N(CC3OCCO3)C=N2)C1=O
Molecular Formula
C11H14N4O4
Molecular Weight
266.25
Precautions
H302
References & Citations
[1]Jiao P, et al. The protective effect of doxofylline against lipopolysaccharides (LPS) -induced activation of NLRP3 inflammasome is mediated by SIRT1 in human pulmonary bronchial epithelial cells. Artif Cells Nanomed Biotechnol. 2020 Dec;48 (1) :687-694. |[2]Riffo-Vasquez Y, et al. Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse. Pulm Pharmacol Ther. 2014 Apr;27 (2) :170-8.|[3]Shukla D, et al. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2009 Oct;10 (14) :2343-56.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Related Products

CatalogName

Popular Products